

Lauren E Walker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4228452/publications.pdf>

Version: 2024-02-01

16
papers

291
citations

1306789

7
h-index

1125271

13
g-index

18
all docs

18
docs citations

18
times ranked

530
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. <i>Journal of Clinical Investigation</i> , 2017, 127, 2118-2132.	3.9	90
2	<scp>WONOEP</scp> appraisal: Molecular and cellular biomarkers for epilepsy. <i>Epilepsia</i> , 2016, 57, 1354-1362.	2.6	81
3	The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite Å-d-N4-hydroxycytidine in human plasma and saliva. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 206, 114356.	1.4	45
4	Highâ€mobility group box 1 as a predictive biomarker for drugâ€resistant epilepsy: A proofâ€ofâ€concept study. <i>Epilepsia</i> , 2022, 63, e1.	2.6	17
5	Prospective clinical trials to investigate clinical and molecular biomarkers. <i>Epilepsia</i> , 2017, 58, 20-26.	2.6	12
6	'Septrin psychosis' among renal transplant patients with <i>Pneumocystis jirovecii</i> pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1117-1119.	1.3	10
7	Pharmacokinetics of Å-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Clinical Infectious Diseases</i> , 2022, 75, e525-e528.	2.9	9
8	Immunomodulatory interventions for focal epilepsy syndromes. <i>The Cochrane Library</i> , 2013, , CDO09945.	1.5	7
9	TEMPORARY REMOVAL: Reference intervals for putative biomarkers of drug-induced liver injury and liver regeneration in healthy human volunteers. <i>Journal of Hepatology</i> , 2018, , .	1.8	4
10	Avoiding harm from overprescribing: What are the challenges and how do we overcome them?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 6-8.	1.1	4
11	Longâ€term bisphosphonate therapy and atypical femoral fracture: Can you have too much of a good thing?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4877-4879.	1.1	3
12	132â€...One year outcomes of heart failure multispecialty multidisciplinary team virtual meetings. , 2021, , .		1
13	Triple antithrombotic therapy and dual therapy â€“ What is the evidence base?. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3009-3012.	1.1	1
14	A European cross-sectional survey to investigate how involved doctors training in clinical pharmacology are in drug concentration monitoring. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1105-1113.	0.8	1
15	Concise advice: Introducing a new clinically focused BJCP series on evidenceâ€based (de)prescribing in challenging situations. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4484-4487.	1.1	0
16	Sodiumâ€glucose coâ€transporterâ€2 inhibitors in the nonâ€diabetic heart failure patient. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	0